Pralatrexate is a new drug that is FDA-approved for lymphoma. The effectiveness of this drug is due in part to the presence of a molecule called RFC-1 on tumor cells, and RFC-1 levels in cancer cells can be increased by treatment wit certain drugs that affect gene expression.
Preliminary data indicate that pralatrexate can also kill myeloma cells that express RFC-1. We will determine if pralatrexate can be combined with drugs that increase RFC-1 to efficiently kill myeloma cells. Proof of this concept in laboratory studies may lead to clinical trials of these combinations in myeloma.